Cethromycin

Cethromycin

File:Cethromycin.png
Systematic (IUPAC) name
(1S,2R,5R,7R,8R,9S,11R,13R,14R)-8-[(2S,3R,4S,6R)- 4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13- hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy] -3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
Clinical data
Routes of administration	Oral
Legal status
Legal status	Phase III Clinical Trials in US
Pharmacokinetic data
Bioavailability	Between 35.8 and 60 % in animal studies.
Metabolism	Liver
Biological half-life	1.6, 3.0, 4.5, 5.9 and 6 hours. Mouse, Monkey, Rat, Dog and Human respectively.
Excretion	7.0% urine 87.2% faeces
Identifiers
CAS Number	205110-48-1
ATC code	none
PubChem	CID 5282045
Chemical data
Formula	C42H59N3O10
Molar mass	765.931 g/mol[[]]
Physical data
Melting point	211 to 213 °C (412 to 415 °F)

Cethromycin (initially known as ABT-773) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On October 1, 2008 Advanced Life Sciences submitted a New Drug Application (NDA) to Food and Drug Administration (FDA) for cethromycin to treat mild-to-moderate community acquired pneumonia.

On December 3, 2008 Advanced Life Sciences announced that this New Drug Application has been accepted for filing by the FDA.

Further reading

• Interaction of the New Ketolide ABT-773 (Cethromycin) with Human Polymorphonuclear Neutrophils and the Phagocytic Cell Line PLB-985 In Vitro. 2004

de:Cethromycin